Sorafenib: In hepatocellular carcinoma

Drugs

Volumn 68, Issue 2, 2008, Pages 251-258

  Simpson, Dene ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Doxorubicin, therapeutic use; Liver cancer, treatment; Sorafenib, general

Indexed keywords

DOXORUBICIN; KETOCONAZOLE; PLACEBO; SORAFENIB;

ABDOMINAL PAIN; ADVANCED CANCER; ALOPECIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; AREA UNDER THE CURVE; BILIRUBIN BLOOD LEVEL; BLEEDING; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; DOXORUBICIN; HUMANS; LIVER NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; TREATMENT OUTCOME;

EID: 38149123239     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868020-00007     Document Type: Review

References (18)

1. Roberts LR, Gores GJ. Emerging drugs for hepatocellular carcinoma. Expert Opin Emerg Drugs 2006; 11 (3): 469-87
2. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006 Dec 15; 66 (24): 11851-8
3. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006 Oct; 5 (10): 835-44
4. Adnane L, Trail PA, Taylor I, et al. Sorafenib (BAY 43-9006, Nexavar®), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2005; 407: 597-612
5. McKeage K, Wagstaff AJ. Sorafenib in advanced renal cancer. Drugs 2007; 67 (3): 475-83
6. Bayer Pharmaceuticals Corporation. Nexavar® becomes first and only approved treatment of hepatocellular carcinoma in Europe [media release]. Available from URL: http://www.press.bayer.com [Accessed 2007 Nov 22]
7. Bayer Pharmaceuticals Corporation. Nexavar® first FDA-approved drug therapy for liver cancer [media release]. Available from URL: http://www.press.bayer.com [Accessed 2007 Nov 21]
8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology™: hepatobiliary cancers. V.2.2008 [online]. Available from URL: http://www.nccn.org [Accessed 2007 Nov 22]
9. Wilhelm SM, Carter C, Tang LY, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004 Oct 1; 64 (19): 7099-109
10. Lierman E, Folens C, Stover EH. Sorafenib is a potent inhibitor of FIP1L1-PDGFR? and the imatinib-resistant FIP1L1-PDGFRα T674I mutant. Blood 2006 Aug 15; 108 (4): 1374-6
11. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006 Sep 10; 24 (26): 4293-300
12. Lathia C, Lettieri J, Cihon F, et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006 May 1; 57 (5): 685-92
13. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92 (10): 1855-61
14. Richly H, Henning BF, Kupsch P, et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006 May; 17 (5): 866-73
15. Bayer Pharmaceuticals Corporation. Nexavar® (sorafenib) tablets, oral: prescribing information [online]. Available from URL: http://www.press. bayer.com [Accessed 2007 Nov 21]
16. Llovet J, Ricci S, Mazzaferro V, et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC) [abstract no. LBA1 plus oral presentation]. American Society of Clinical Oncology 43rd Annual Meeting; 2007 Jun 1-5; Chicago (IL)
17. Abou-Alfa G, Johnson P, Knox J, et al. Final results from a phase II (PhII), randomized, double-blind study of sorafenib plus doxorubicin (S+D) versus placebo plus doxorubicin (P+D) in patients (pts) with advanced hepatocellular carcinoma (AHCC) [abstract plus slide presentation]. 14th European Cancer Conference; 2007 Sep 23-27; Barcelona
18. European Medicines Agency. Sorafenib (Nexavar): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu [Accessed 2007 Nov 21]